Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

NCT07762027 is registered in ClinicalTrials.gov with Assembly Biosciences as lead sponsor.

NCT NCT07762027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07762027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
Lead sponsor
Assembly Biosciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
September 30, 2028
Enrollment
80 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis d infection